Sambrook et al., 1993 - Google Patents

Diagnosis and treatment of osteoporosis

Sambrook et al., 1993

Document ID
7371970723305507929
Author
Sambrook P
Eisman J
Publication year
Publication venue
Current Opinion in Rheumatology

External Links

Snippet

Risk of osteoporotic fracture is dependent on peak bone mass achieved at skeletal maturity and subsequent bone loss. Accordingly, reduction in this risk can be achieved by maximizing the peak bone mass, preventing subsequent bone loss, or increasing bone …
Continue reading at journals.lww.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P-C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/56—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
    • A61B17/58—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor for osteosynthesis, e.g. bone plates, screws, setting implements or the like
    • A61B17/68—Internal fixation devices, including fasteners and spinal fixators, even if a part thereof projects from the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Similar Documents

Publication Publication Date Title
Ravn et al. Premenopausal and postmenopausal changes in bone mineral density of the proximal femur measured by dual‐energy x‐ray absorptiometry
Bakalov et al. Bone mineral density and fractures in Turner syndrome
Lapauw et al. Body composition, volumetric and areal bone parameters in male-to-female transsexual persons
LUCKEY et al. Radial and vertebral bone density in white and black women: evidence for racial differences in premenopausal bone homeostasis
Evans et al. Bone mass is low in relatives of osteoporotic patients
Nguyen et al. Lifestyle factors and bone density in the elderly: implications for osteoporosis prevention
Nilas et al. Bone mass and its relationship to age and the menopause
Seeman Osteoporosis in men: epidemiology, pathophysiology, and treatment possibilities
Reid et al. Determinants of the rate of bone loss in normal postmenopausal women
Smeets-Goevaers et al. The prevalence of low bone mineral density in Dutch perimenopausal women: the Eindhoven perimenopausal osteoporosis study
Guggenbuhl Osteoporosis in males and females: is there really a difference?
Dennison et al. Determinants of bone loss in elderly men and women: a prospective population-based study
Garnero et al. Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. The OFELY study
Scane et al. Case-control study of the pathogenesis and sequelae of symptomatic vertebral fractures in men
Hla et al. A multicenter study of the influence of fat and lean mass on bone mineral content: evidence for differences in their relative influence at major fracture sites. Early Postmenopausal Intervention Cohort (EPIC) Study Group
Garnero et al. A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover
Hansen et al. Is heritability a risk factor for postmenopausal osteoporosis?
Kim et al. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis
Overgaard et al. Discriminatory ability of bone mass measurements (SPA and DEXA) for fractures in elderly postmenopausal women
Dresner-Pollak et al. Increased urinary N-telopeptide cross-linked type 1 collagen predicts bone loss in patients with inflammatory bowel disease
Revilla et al. Influence of body mass index on the age-related slope of total and regional bone mineral content
Huang et al. One-year soy isoflavone supplementation prevents early postmenopausal bone loss but without a dose-dependent effect
Delmas et al. A dose-ranging trial of a matrix transdermal 17β-estradiol for the prevention of bone loss in early postmenopausal women
Grey et al. Accelerated bone loss in post‐menopausal women with mild primary hyperparathyroidism
Forsmo et al. How do reproductive and lifestyle factors influence bone density in distal and ultradistal radius of early postmenopausal women? The Nord-Trøndelag Health Survey, Norway